Experimental cocktail targets Hard-to-Treat lymphomas

NCT ID NCT01846390

Completed Disease control Sponsor: Canadian Cancer Trials Group Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested a combination of four drugs—romidepsin, gemcitabine, dexamethasone, and cisplatin—in 21 people with peripheral T-cell or diffuse large B-cell lymphoma who had already tried other treatments. The main goal was to find a safe dose of romidepsin when added to the standard GDP chemotherapy. Researchers also looked at side effects and whether the combo might work better than existing options.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: romidepsin, gemcitabine, dexamethasone, cisplatin
What this could lead to: If successful, this could lead to a more effective chemotherapy combination for certain lymphomas, potentially improving survival.
What could go wrong: This is a very early Phase I trial with only 21 participants, focused on safety and dosing. It is too small to prove effectiveness, and side effects may be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma mature T-cell and NK-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIFFUSE LARGE B-CELL LYMPHOMA PERIPHERAL T-CELL LYMPHOMA

Contacts and locations

Locations

BCCA - Vancouver Cancer Centre

Vancouver, British Columbia, V5Z 4E6, Canada
Odette Cancer Centre

Toronto, Ontario, M4N 3M5, Canada
QEII Health Sciences Centre

Halifax, Nova Scotia, B3H 1V7, Canada
Regional Health Authority B, Zone 2

Saint John, New Brunswick, E2L 4L2, Canada
Tom Baker Cancer Centre

Calgary, Alberta, T2N 4N2, Canada
Univ. Health Network-Princess Margaret Hospital

Toronto, Ontario, M5G 2M9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.